Drug Trial News

RSS
Participants in clinical trials value personalized, accurate information about study results

Participants in clinical trials value personalized, accurate information about study results

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Promising trials of malaria vaccine in East Africa lead to calls for phase 3 development

Promising trials of malaria vaccine in East Africa lead to calls for phase 3 development

Novel approach to disseminate trial results to study volunteers

Novel approach to disseminate trial results to study volunteers

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

RHEI Pharmaceuticals starts final trial of Tibozole in China

RHEI Pharmaceuticals starts final trial of Tibozole in China

MedImmune starts phase 2 trial of antibody targeting IL-5 receptor

MedImmune starts phase 2 trial of antibody targeting IL-5 receptor

Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation

Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

Allos Therapeutics announces results from phase 2 trial of Pralatrexate in peripheral T-cell lymphoma

Allos Therapeutics announces results from phase 2 trial of Pralatrexate in peripheral T-cell lymphoma

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

New data demonstrates efficacy and tolerability of Carisbamate as an adjunctive therapy for partial onset seizures

New data demonstrates efficacy and tolerability of Carisbamate as an adjunctive therapy for partial onset seizures

Daiichi Sankyo starts trial of investigational factor Xa inhibitor for atrial fibrillation

Daiichi Sankyo starts trial of investigational factor Xa inhibitor for atrial fibrillation

Hep C treatment peginterferon reduces the virus but liver damage continues

Hep C treatment peginterferon reduces the virus but liver damage continues

Clinical study shows that drug improves endothelial function in sickle cell disease patients

Clinical study shows that drug improves endothelial function in sickle cell disease patients

ACE inhibitor calcium channel blocker combo drug shown to reduces heart attacks

ACE inhibitor calcium channel blocker combo drug shown to reduces heart attacks

Low-dose peginterferon used for hepatitis C doesn't work

Low-dose peginterferon used for hepatitis C doesn't work

SemBioSys begins phase I/II trial of insulin produced in plant seeds

SemBioSys begins phase I/II trial of insulin produced in plant seeds

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.